证券代码：301093 证券简称：华兰股份 公告编号：2025-095 江苏华兰药用新材料股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"公司"）第六届董事会第五 次会议通知于 2025 年 9 月 12 日以邮件、电话等方式向各位董事发出，会议于 2025 年 9 月 19 日以现场会议结合通讯形式召开。本次会议由公司董事长华一敏 先生召集并主持，应出席会议的董事 9 人，实际出席会议的董事 9 人，其中华 一敏先生、肖锋先生、崔珂女士、姚茗芳女士、单体超先生、陈岗先生、刘力 先生、侯绪超先生以通讯表决方式出席本次董事会会议，公司高级管理人员列 席了会议。本次会议的召集、召开及表决符合《公司法》等有关法律、法规、 规范性文件和《公司章程》的规定，会议合法、有效。 二、 董事会会议审议情况 1、会议以 8 票同意、0 票反对、0 票弃权，审议通过了《关于公司<2025 年员工持股计划（草案）>及其摘要的议案》。 为了进一步建立、健全公司长效奖励机制 ...

Group 1 - The core point of the article is that Hualan Biological Engineering Co., Ltd. announced a board meeting to discuss the employee stock ownership plan for 2025 [1] - The meeting was held on September 19, 2025, in a combination of in-person and communication formats [1] - For the first half of 2025, Hualan's revenue composition was 99.07% from the pharmaceutical manufacturing industry and 0.93% from other businesses [1] Group 2 - As of the report, Hualan's market capitalization is 6.3 billion yuan [1]

格隆汇9月19日丨华兰股份(301093.SZ)公布2025年员工持股计划，本员工持股计划拟筹集资金总额（含 预留份额）上限为5,685.24万元，以"股"作为认购单位，单个员工必须认购整数倍股数。奖励基金上限 为2,484.92万元，激励基金将根据权责发生制原则计入当期费用。本员工持股计划的标的股票来源为公 司回购专用证券账户回购的公司A股普通股股票。本员工持股计划经公司股东会批准后，回购专用证券 账户的股份将通过非交易过户等法律法规允许的方式转让给本员工持股计划，本员工持股计划持有的标 的股票数量不超过292.00万股，约占公司当前总股本的1.78%。 ...

北京植德律师事务所 关于江苏华兰药用新材料股份有限公司 2025 年员工持股计划的 法律意见书 二〇二五年九月 北京市东城区东直门南大街1 号来福士中心办公楼 12 层 邮编:100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel):010-56500900 传真(Fax):010-56500999 www.meritsandtree.com Merits Tree 植德 北京植德律师事务所 关于江苏华兰药用新材料股份有限公司 2025 年员工持股计划的 法律意见书 植德(证)字[2025]0044-1 号 致:江苏华兰药用新材料股份有限公司 北京植德律师事务所(以下称"本所")接受江苏华兰药用新材料股份有限 公司(以下称"华兰股份"或"公司")的委托,担任公司实施 2025年员工持 股计划(以下简称"本次员工持股计划")的专项法律顾问。 植德(证)字[2025]0044-1 号 根据《中华人民共和国公司 ...

江苏华兰药用新材料股份有限公司 2025 年员工持股计划 管理办法 二〇二五年九月 1 第一章 总则 第一条 为规范江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司" 或"本公司"）2025年员工持股计划（以下简称"员工持股计划"或"本计划"或"本 持股计划"或"本员工持股计划"）的实施，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《关 于上市公司实施员工持股计划试点的指导意见》（以下简称"《指导意见》"）、《深 圳证券交易所上市公司自律监管指引第 2号——创业板上市公司规范运作（2025 年修 订）》（以下简称"《自律监管指引第 2号》"）等相关法律、行政法规、规章、规范 性文件、《公司章程》及《江苏华兰药用新材料股份有限公司 2025年员工持股计划（草 案）》之规定，特制定《江苏华兰药用新材料股份有限公司 2025年员工持股计划管理办 法》（以下简称"《员工持股计划管理办法》"）。 2 第二章 员工持股计划的制定 第二条 员工持股计划所遵循的基本原则 （一）依法合规原则 公司实施员工持股计划，严格按照法律、行政法规的规定履行程序 ...

Core Viewpoint - Hualan Co., Ltd. is accelerating capital recovery by selling a 30% stake in Jiaxing Yuanfan Venture Capital Partnership for RMB 12 million, which is aligned with the company's strategic layout and future development plans, aiming to enhance asset operation efficiency and improve financial status [2][6] Financial Performance - In 2024, Hualan Co., Ltd. reported a revenue of RMB 586 million, a decrease of 5.86% year-on-year, and a net profit of RMB 49.57 million, down 57.96% year-on-year [7] - The company experienced a significant decline in net profit due to fluctuations in downstream demand, changes in product structure, and increased depreciation and amortization expenses [7] - In the first half of 2025, Hualan Co., Ltd. achieved a revenue of RMB 309 million, an increase of 8.82% year-on-year, and a net profit of RMB 43.73 million, up 18.27% year-on-year, with a non-GAAP net profit growth of 42.18% [8] Stock Performance - Since August 2024, Hualan Co., Ltd.'s stock price has entered an "upward channel," increasing by approximately 160% over the past year [9][10] - The company has conducted share buybacks, utilizing a total of RMB 99.98 million for repurchasing shares, which has contributed to the stock price increase [10] Dividends - Hualan Co., Ltd. has distributed dividends four times since its listing, with a total dividend amount of RMB 238 million, maintaining a dividend payout ratio exceeding 40% in the past three years [11]

Core Viewpoint - Hualan Co., Ltd. has signed an agreement to transfer its 30% stake in Jiaxing Yuanfan to Shanghai Hongyuan Investment Group for RMB 12 million, aligning with its strategic layout and future development plans [1] Group 1: Transaction Details - The company will sell its 30% property share in Jiaxing Yuanfan, which includes a subscribed capital of RMB 30 million and a paid-in capital of RMB 12 million, for RMB 12 million [1] - After the transfer, the company will no longer hold any property shares in Jiaxing Yuanfan [1] Group 2: Strategic Implications - The transaction is aimed at improving the company's financial situation by recovering funds and allowing the company to focus on its core business [1] - The move is expected to enhance asset operation efficiency and have a positive impact on the company's financial status [1] - The transaction was conducted under principles of openness, fairness, and justice, ensuring no harm to the interests of the company and its shareholders [1]

Core Viewpoint - The company has signed a partnership asset transfer agreement with Shanghai Hongyuan Investment Group, transferring 30% of its stake in Jiaxing Yuanfan Venture Capital Partnership, which is expected to enhance financial efficiency and focus on core business operations [1] Group 1 - The company will transfer its 30% stake in Jiaxing Yuanfan, with a subscribed capital of 30 million yuan and a paid-in capital of 12 million yuan, for a transfer price of 12 million yuan [1] - After the completion of the transfer, the company will no longer hold any stake in Jiaxing Yuanfan [1] - This transaction is beneficial for the company to recover funds and improve asset operation efficiency, positively impacting its financial status [1]

一、 交易概述 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）于 2023 年 5 月 26 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于参与投资 设立新产业投资基金的公告》（公告编号：2023-046），公司与上海元藩投资有 限公司、上海鸿元投资集团有限公司、盛雷鸣、潘苏航共同签署了《嘉兴远帆 创业投资合伙企业（有限合伙）之有限合伙协议》（以下简称"合伙协议"），拟 共同设立嘉兴远帆创业投资合伙企业（有限合伙）（以下简称"合伙企业"或 "嘉兴远帆"）。合伙企业本期计划募集资金人民币 10,000 万元，其中公司作为 有限合伙人拟以自有资金出资认缴人民币 3,000 万元，占合伙企业认缴出资额 的 30%。2023 年 10 月 24 日，公司在巨潮资讯网（www.cninfo.com.cn）披露了 《关于参与投资设立新产业投资基金的进展公告》（公告编号：2023-076）。 近日，公司基于战略布局和未来发展规划，经与嘉兴远帆各方充分沟通并 友好协商，公司与上海鸿元投资集团有限公司签署了《合伙企业财产份额转让 协议》（以下简称"本协议"），将公司持有嘉兴远帆 30%的财产 ...

Market Overview - On September 17, the medical device sector experienced a decline of 0.22%, with Toujing Life leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Notable gainers in the medical device sector included: - Hualan Biological (301093) with a closing price of 39.01, up 5.20% and a trading volume of 85,900 shares, totaling a transaction value of 330 million yuan [1] - Xinhua Medical (600587) closed at 17.16, up 5.08% with a trading volume of 451,500 shares, totaling 767 million yuan [1] - Haooubo (688656) closed at 168.52, up 5.00% with a trading volume of 16,600 shares, totaling 272 million yuan [1] - Conversely, the following companies saw significant declines: - Toujing Life (300642) closed at 24.55, down 7.53% with a trading volume of 168,900 shares, totaling 426 million yuan [2] - Jimin Health (603222) closed at 13.22, down 4.06% with a trading volume of 748,900 shares, totaling 995 million yuan [2] - Meihua Medical (301363) closed at 27.31, down 2.95% with a trading volume of 153,300 shares, totaling 422 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 894 million yuan from institutional investors, while retail investors contributed a net inflow of 818 million yuan [2] - Notable capital flows included: - Haooubo (688656) with a net inflow of 39.06 million yuan from institutional investors, but a net outflow of 23.69 million yuan from speculative funds [3] - Xinhua Medical (600587) had a net inflow of 38.89 million yuan from institutional investors, with a net outflow of 64.90 million yuan from speculative funds [3] - Hualan Biological (301093) recorded a net inflow of 24.68 million yuan from institutional investors, while retail investors saw a net outflow of 25.99 million yuan [3]